An anti-tumor memory response was observed in 67% (2/3) of mice previously treated with BEMPEG, anti-CTLA-4, and RT – as determined by the rejection of re-engraftment with LLC (Supplemental Figure 2). Here, CTLA4 is linked to neoplasm.